source
- Ascletis oral GLP-1 candidate ASC30 meets primary and secondary goals in phase 2 diabetes studyAscletis reported that its oral GLP-1 small‑molecule candidate ASC30 achieved both its primary and secondary endpoints in a phase 2 trial involving 100 patients with type 2 diabetes. The study sho…
- Oura and UC San Diego Health launch trial linking smart ring data to obesity treatment outcomesOura and UC San Diego Health have partnered on a multi-year clinical trial called SMART-BMI to explore how continuous data from the Oura Ring may reflect patient response to obesity therapies. The…